Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 10;20(6):e0325423.
doi: 10.1371/journal.pone.0325423. eCollection 2025.

Additive effect of diabetes mellitus on the prevalence and prognosis of sarcopenic obesity: Implications for all-cause mortality

Affiliations

Additive effect of diabetes mellitus on the prevalence and prognosis of sarcopenic obesity: Implications for all-cause mortality

Ting-Ju Kuo et al. PLoS One. .

Abstract

Diabetes mellitus (DM) and sarcopenic obesity are common conditions associated with increased morbidity and mortality. DM, characterized by chronic hyperglycemia, is a recognized risk factor for cardiovascular disease and premature death. Sarcopenic obesity, characterized by reduced muscle mass and increased adiposity, contributes to physical frailty and metabolic dysfunction. This study investigated the effect of DM on mortality rates and causes of death among individuals with high adiposity and low muscle mass (HA-LM) by using data from the National Health and Nutrition Examination Survey (NHANES) linked to mortality records from 2011 to 2018. A total of 2366 patients with HA-LM patients were analyzed, including 194 (8.199%) with DM and 2172 (91.80%) without DM. During the study period, the mortality rate was 1.19% in the HA-LM without DM group and 5.15% in the HA-LM with DM group. Kaplan-Meier survival analysis demonstrated a significantly higher mortality rate in the HA-LM patients with DM group, supported by both crude (hazard ratio [HR]: 4.34, 95% confidence interval [CI]: 2.09-9.00, p < 0.001) and adjusted (HR: 2.88, 95% CI: 1.23-6.73, p < 0.01) models. Cause-specific analysis revealed that heart disease (40%) was the leading cause of mortality in the HA-LM with DM group, followed by other residual causes (30%). By contrast, other residual causes were predominant among those without DM (34.62%), followed by malignant neoplasms (19.23%). These findings underscore the synergistic effects of DM and sarcopenic obesity on the risk of mortality and emphasize the need for targeted interventions aimed at managing diabetes and preserving muscle mass. The study findings may inform interventions aimed at improving health outcomes and reducing mortality in this high-risk population.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Kaplan-Meier survival estimates of mortality.
Fig 2
Fig 2. Causes of mortality among patients with HA-LM with and without DM.
Cause of Death: Recode: 001 Heart disease (054–068). 002 Malignant neoplasms (019–043). 003 Chronic lower respiratory diseases (082–086). 004 Accidents (unintentional injuries) (112–123). 005 Cerebrovascular diseases (070). 006 Alzheimer’s disease (052). 007 Diabetes mellitus (046). 008 Influenza and pneumonia (076–078). 009 Nephritis, nephrotic syndrome and nephrosis (097–101). 010 All other causes (residual).

Similar articles

References

    1. Han H, Cao Y, Feng C, Zheng Y, Dhana K, Zhu S. Association of a healthy lifestyle with all-cause and cause-specific mortality among individuals with type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2022. - PubMed
    1. Atkins JAO, Wannamathee SG. Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr. 2020. - PubMed
    1. Wannamethee SA-O, Atkins JL. Sarcopenic obesity and cardiometabolic health and mortality in older adults: a growing health concern in an ageing population. Curr Diab Rep. 2023. - PMC - PubMed
    1. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020. - PubMed
    1. Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020. - PubMed